At @ weeks postrandomization , mean HbA@c changes were noninferior for exenatide compared with lispro ( -@ and -@ % , respectively ) ; treatment differences were -@ ( @ % CI -@ , @ ) in per-protocol ( n = @ ) and -@ ( @ % CI -@ , @ ) in intent-to-treat ( n = @ ) populations .